nature portfolio

Corresponding author(s):	Levent Beker
Last updated by author(s):	Dec 10, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

\sim				
<.	tat	ΙIC	:11	\sim

For	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	firmed
	\boxtimes	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
\boxtimes		A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
\boxtimes		The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes		A description of all covariates tested
\boxtimes		A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes		For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
\boxtimes		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes		Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.

Software and code

Policy information about <u>availability of computer code</u>

Data collection

A commercial ultrasound imaging scanner (Toshiba Nemio 10) was used for ultrasound imaging of the bladder. A commercial digital blood pressure cuff was used to obtain blood pressure values. Picoscope was used to acquire and save the raw ultrasonic signals from the reported US tags.

Data analysis

Origin 2019 and Python 3 were used for the analysis.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The main data and material resources supporting the results of this study are available within the article and its Supplementary Information. Source data can also be found within the article. Raw data will be available in KU Research Data Repository (KU-RDR) as soon as possible.

Research	involving	human	narticina	nts thair	data	or high	مهندعا	material
nesearch	IIIVOIVIIIg	Hulliali	participal	nts, then	uala,	יוטוע וט	ogicai	matenai

and sexual orientation		thinicity and racism.			
Reporting on sex and					
Reporting on race, ethnicity, or other socially relevant groupings		Race is not a variable affecting the methodology and hence, was not considered.			
Population characte	aracteristics Healthy subject, 29 years old				
Recruitment		The subject consented to this study			
Ethics oversight		Koc University Ethics Committee (2023.006.IRB2.004)			
Note that full information on the approval of the study protocol must also be provided in the manuscript.					
ministrativa e e e	. (.				
Field-spec					
	below that is —	the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
Life sciences		ehavioural & social sciences			
For a reference copy of the c	document with a	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>			
Life scienc	es stu	ıdy design			
All studies must disclo	se on these	points even when the disclosure is negative.			
Sample size Or	One consenting and healthy participants was recruited				
Data exclusions No	No data were excluded				
Replication	Ultrasonic device measurements were performed on the participant multiple times to verify the reproducibility of the results				
Randomization n-	ation n-a				
Blinding	No blinding measures were taken, and the acquired data were analyzed by two authors				
Reporting	for sp	pecific materials, systems and methods			
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.			
Materials & exper	rimental sy	ystems Methods			
n/a Involved in the study		n/a Involved in the study			
Antibodies		ChIP-seq			
Eukaryotic cell lines		Flow cytometry			
Clinical data					
Dual use research of concern					
Plants					

Plants

Seed stocks

Report on the source of all seed stocks or other plant material used. If applicable, state the seed stock centre and catalogue number. If plant specimens were collected from the field, describe the collection location, date and sampling procedures.

Novel plant genotypes

Describe the methods by which all novel plant genotypes were produced. This includes those generated by transgenic approaches, gene editing, chemical/radiation-based mutagenesis and hybridization. For transgenic lines, describe the transformation method, the number of independent lines analyzed and the generation upon which experiments were performed. For gene-edited lines, describe the editor used, the endogenous sequence targeted for editing, the targeting guide RNA sequence (if applicable) and how the editor was applied.

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to

Authentication

Describe any authentication procedures for each seed stock used or novel genotype generated. Describe any experiments used to assess the effect of a mutation and, where applicable, how potential secondary effects (e.g. second site T-DNA insertions, mosiacism, off-target gene editing) were examined.